Zydus Cadila bags USFDA nod for Topiramate extended
DSIJ Intelligence / 27 Nov 2017
Pharma major Zydus Cadila bagged the approval of the US Food and Drugs Association to market Topiramate Extended in 25 mg, 50 mg and 100 mg on Monday.
Pharma major Zydus Cadila bagged the approval of the US Food and Drugs Association to market Topiramate Extended in 25 mg, 50 mg and 100 mg on Monday. The company also received USFDA approval to market Minocycline Hydrochloride extended and Tadalafil Tablets USP, recently.
Toparimate extended, to be manufactured at the company’s Ahmedabad facility, is used for the treatment of seizures and migraine headaches. The company has over 170 USFDA approvals and has filed over 310 ANDAs over time.
However, the stock has been trading flat in Monday’s intraday trade. The stock hit an intraday high of Rs. 447 per share and an intraday low of Rs. 442 per share on BSE. The stock had hit its 52-week high of Rs. 558 per share on June 12, 2017 and its intraday low of Rs. 329.95 per share on December 26, 2016, respectively.
At 12:40 hours, the stock was trading at Rs. 442.55 per share, lower by 0.83 per cent on Monday.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.